Galunisertib (LY2157299, GAL) stands out as a selective ATP-competitive inhibitor of TGFBR1(ALK5) and is the only inhibitor of the TGF-β pathway used in clinical studies in HCC patients (NCT01246986) [39, 40]. Here, TGFB1 is linked to hepatocellular carcinoma.